Clinical Trial Update: Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing inhaled TPI-1020 to inhaled budesonide in COPD patients reports safety, tolerability and pharmacodynamic activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide (BUDESONIDE)
• TPI-1020 (TPI-1020)

Snippet

Sponsor: Syntara | Conditions: Copd Bronchitis | Phase 2 | Status: COMPLETED